Inventor · disambiguated record
Mark Laughlin
Also filed as: LAUGHLIN MARK · LAUGHLIN MARK A
6 granted patents·12 pending applications·132 citations·filing 2000–2010
83Inventor score
Top patents by PatentIndex Score
18 records- 0197US6689765B2Piperazine derivatives useful as CCR5 antagonistsSCHERING CORP·Filed 2002·Granted Feb 10, 2004·71 cites·12 claims
- 0287US6635646B1Pegylated interferon alfa-CCR5 antagonist combination HIV therapySCHERING CORP·Filed 2000·Granted Oct 21, 2003·33 cites·30 claims
- 0385US6602885B2Piperidine derivatives useful as CCR5 antagonistsSCHERING CORP·Filed 2001·Granted Aug 5, 2003·21 cites·17 claims
- 0478US7384944B2Piperazine derivatives useful as CCR5 antagonistsSCHERING CORP·Filed 2003·Granted Jun 10, 2008·6 cites·18 claims
- 0567US7247631B2Pegylated interferon alfa-CCR5 antagonist combination HIV therapySCHERING CORP·Filed 2003·Granted Jul 24, 2007·1 cites·10 claims
- 0665US8114879B2Piperazine derivatives useful as CCR5 antagonistsBAROUDY BAHIGE M·Filed 2008·Granted Feb 14, 2012·0 cites·14 claims
- 0758US2010129470A1Method of treating brain cancerMYRIAD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0858US2010087458A1Method of treating melanomaMYRIAD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0958US2010093773A1Methods of treating cancerMYRIAD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1058US2010087457A1Dosages and methods for the treatment of cancerMYRIAD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1157US2010137342A1Methods for treating vascular disruption disordersMYRIAD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1253US2007004635A1Method of treating interferon non-responders using HCV protease inhibitorSCHERING CORP·Filed 2006·Application pending·0 cites
- 1352US2008033045A1Treatment of psychiatric disordersMYRIAD GENETICS INC·Filed 2007·Application pending·0 cites
- 1451US2004058974A1Treating fungal infectionsSCHERING CORP·Filed 2003·Application pending·0 cites
- 1550US2007015832A1Methods of treating overactive bladder and urinary incontinenceMYRIAD GENETICS INC·Filed 2006·Application pending·0 cites
- 1639US2002182179A1HIV TherapyFiled 2000·Application pending·0 cites
- 1737US2010261739A1Method of Treating Non-Small Cell Lung CancerMYRIAD PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 1835US2002004584A1HIV immune adjuvant therapyFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Laughlin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →